Pan J, Zheng QZ, Li Y, et al. - For the early diagnosis of esophageal squamous cell carcinoma (ESCC), researchers assessed a four-autoantibody panel (ie, anti-TP53, HRAS, CTAG1A, and NSG1) in this study comprising a training set and data from an independent validation set. They focused on the performance of this panel and for this, they analyzed 569 retrospective serum samples. A significant differentiation of early ESCC cases from the controls was enabled by this four-autoantibody panel, with 62.8% sensitivity at 88.9% specificity in the training set and with 58.0% sensitivity at 90.0% specificity in the independent validation set. Findings revealed the good performance of this four-autoantibody panel for early ESCC diagnosis with ELISA. Using the Luminex xMAP technology, this panel could be further developed into a multiplex assay.